Your browser doesn't support javascript.
loading
The heme biosynthetic pathway in lymphocytes of patients with malignant lymphoproliferative disorders.
Schoenfeld, N; Epstein, O; Lahav, M; Mamet, R; Shaklai, M; Atsmon, A.
Afiliación
  • Schoenfeld N; Laboratory of Biochemical Pharmacology, Beilinson Medical Center, Petah Tiqva, Israel.
Cancer Lett ; 43(1-2): 43-8, 1988 Dec 01.
Article en En | MEDLINE | ID: mdl-3203329
ABSTRACT
The metabolism of heme is impaired in lymphocytes of patients with malignant lymphoproliferative disorders (MLPO). Two of the enzymes of the heme biosynthetic pathway, delta-aminolevulinic acid dehydrase (ALAD) (EC 4.2.1.24) and ferrochelatase (FC) (EC 4.99.1.1) are markedly reduced. The activity of porphobilinogen deaminase (PBGD) (EC 4.3.1.8) is increased. The rate-limiting enzyme of heme biosynthesis in the liver, aminolevulinate synthase (ALAS) (EC 2.3.1.37) remains unchanged although the concentration of total heme in the lymphocytes is markedly reduced. This might reflect a lack of negative feedback inhibition by heme on ALAS activity in this system.
Asunto(s)
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Linfocitos / Hemo / Trastornos Linfoproliferativos Límite: Humans Idioma: En Año: 1988 Tipo del documento: Article
Buscar en Google
Banco de datos: MEDLINE Asunto principal: Linfocitos / Hemo / Trastornos Linfoproliferativos Límite: Humans Idioma: En Año: 1988 Tipo del documento: Article